NEW DELHI: No vaccine has yet been approved for commercial use against Covid-19 but over a dozen vaccines from more than a 100 candidates globally are being tested in humans. India making its headway in the vaccine race earlier this week allowed one of the vaccine candidates to move to human clinical trials.
What is Covaxin
Covaxin is India’s first vaccine candidate to have gone into human clinical trials.
Bharat Biotech, the Hyderabad-based vaccine major, announced this week that its Covid-19 vaccine candidate has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.
The Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response.
Human clinical trials are scheduled to start across India in July 2020.